SUPN Supernus Pharmaceuticals Inc.

39.00
-0.40  -1%
Previous Close 39.40
Open 39.35
Price To book 8.63
Market Cap 1977265290
Shares 50,699,110
Volume 670,382
Short Ratio 7.38
Av. Daily Volume 800,213

SEC filingsSee all SEC filings

  1. 8-K - Current report 171094311
  2. 8-K - Current report 171039140
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171004706
  4. 8-K - Current report 171000918
  5. 8-K - Current report 17976683

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
Phase 2b trial met primary endpoint - October 11, 2016. Phase 3 planned for 2H 2017.
SPN-812
ADHD
Phase 3 enrollment to continue through mid-2018. Noted September 18, 2017 that the lower of the two doses will be discontinued following interim analysis.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine

SEC Filings

  1. 8-K - Current report 171094311
  2. 8-K - Current report 171039140
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171004706
  4. 8-K - Current report 171000918
  5. 8-K - Current report 17976683
  6. CT ORDER - Confidential treatment order 17935512
  7. 8-K - Current report 17928130
  8. 8-K - Current report 17909403
  9. 8-K - Current report 17888492
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827537